Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) plus Inlyta (Pfizer), are revolutionizing the treatment of advanced disease. The approval and uptake of Opdivo plus Cabometyx (Exelixis / Ipsen) and Keytruda plus Lenvima / Kisplyx (Eisai) will also drive fierce competition in this setting. Treatment choices for early-stage disease are also increasing with Keytruda’s label expansion as an adjuvant therapy. Moreover, the FDA’s approval of Welireg (Merck & Co.) will reshape the treatment of VHL-associated tumors. The anticipated entry of other agents such as savolitinib (AstraZeneca) will further diversify treatment options during the forecast period and create a highly competitive and dynamic market.
Questions answered
- What is the size of the early-stage and advanced / metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, Welireg, Lenvima / Kisplyx, and Keytruda for renal cell carcinoma?
- Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
- What are the drivers and constraints in renal cell carcinoma, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Q4 2022
- November 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Q2 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- Q4 2022
- Market outlook
- Key findings
- Market share of drug classes for renal cell carcinoma: 2021
- Market share of drug classes for renal cell carcinoma: 2031
- Drug-treatable population share and major-market sales share in renal cell carcinoma: 2021
- Drug-treatable population share and major-market sales share in renal cell carcinoma: 2031
- Population positioning of current therapies in renal cell carcinoma
- Population positioning of emerging therapies in renal cell carcinoma
- Renal cell carcinoma SWOT analysis
- Market drivers and constraints
- What factors are driving the market for renal cell carcinoma?
- What factors are constraining the market for renal cell carcinoma?
- Major-market sales for renal cell carcinoma by drug-treatable population: 2021-2031
- Major-market sales of immune oncology therapies for renal cell carcinoma: 2021-2031
- Major-market sales of angiogenesis inhibitors for renal cell carcinoma: 2021-2031
- Segment-specific trends
- Patient-share dynamics of therapies for early-stage (stage I-III) renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
- Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, United States, 2021-2031
- Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Progression of renal cell carcinoma
- Anatomy and histology of renal cell carcinoma
- Prognostic models for renal cell carcinoma
- International Metastatic RCC Database Consortium risk assessment system for stage IV renal cell carcinoma
- UCLA Integrated Staging System for renal cell carcinoma
- Classification of renal cell carcinoma
- Staging of renal cell carcinoma
- TNM staging system for renal cell carcinoma
- Definitions of the TNM staging system for renal cell carcinoma
- Key pathways and drug targets for renal cell carcinoma
- Disease overview
- Epidemiology
- Key findings
- Key updates
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of renal cell carcinoma
- Diagnosed incident cases of renal cell carcinoma: 2021-2031
- Disease definition
- Methods
- Sources used for stage distribution of renal cell carcinoma
- Diagnosed incident cases of renal cell carcinoma by stage distribution: 2021-2031
- Disease definition
- Methods
- Sources used for recurrent incidence of renal cell carcinoma
- Recurrent incident cases of renal cell carcinoma: 2021-2031
- Renal cell carcinoma patient flow
- Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
- Drug-treated cases of renal cell carcinoma: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for renal cell carcinoma
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for renal cell carcinoma
- Current treatments used for renal cell carcinoma
- Market events influencing the use of key current therapies in renal cell carcinoma
- Key results from select clinical trials investigating Opdivo for the treatment of renal cell carcinoma
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of renal cell carcinoma
- Expert insight: Opdivo
- Key results from select clinical trials investigating Opdivo and Yervoy combination therapy for the treatment of renal cell carcinoma
- Ongoing clinical development of Opdivo and Yervoy combination therapy
- Key ongoing clinical trials of Opdivo and Yervoy combination therapy in the treatment of renal cell carcinoma
- Expert insight: Opdivo and Yervoy combination therapy
- Key results from select clinical trials investigating Keytruda for the treatment of renal cell carcinoma
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of renal cell carcinoma
- Expert insight: Keytruda
- Key results from select clinical trials investigating Bavencio for the treatment of renal cell carcinoma
- Ongoing clinical development of Bavencio
- Expert insight: Bavencio
- Key results from select clinical trials investigating Sutent for the treatment of renal cell carcinoma
- Expert insight: Sutent
- Key results from select clinical trials investigating Votrient for the treatment of renal cell carcinoma
- Expert insight: Votrient
- Advantages and disadvantages of Nexavar
- Expert insight: Nexavar
- Key results from select clinical trials investigating Inlyta for the treatment of renal cell carcinoma
- Expert insight: Inlyta
- Expert insight: Avastin
- Key results from select clinical trials investigating Cabometyx for the treatment of renal cell carcinoma
- Ongoing clinical development of Cabometyx
- Key ongoing clinical trials of Cabometyx in the treatment of renal cell carcinoma
- Expert insight: Cabometyx
- Key results from select clinical trials investigating Lenvima / Kisplyx for the treatment of renal cell carcinoma
- Ongoing clinical development of Lenvima / Kisplyx
- Expert insight: Lenvima / Kisplyx
- Key results from select clinical trials investigating Fotivda for the treatment of renal cell carcinoma
- Ongoing clinical development of Fotivda
- Key ongoing clinical trials of Fotivda in the treatment of renal cell carcinoma
- Expert insight: Fotivda
- Advantages and disadvantages of Torisel
- Expert insight: Torisel
- Ongoing clinical development of Afinitor
- Key ongoing clinical trials of Afinitor in the treatment of renal cell carcinoma
- Expert insight: Afinitor
- Key results from select clinical trials investigating Welireg for the treatment of renal cell carcinoma
- Ongoing clinical development of Welireg
- Key ongoing clinical trials of Welireg in the treatment of renal cell carcinoma
- Expert insight: Welireg
- Medical practice
- Early-stage renal cell carcinoma: stages I-III
- First-line advanced or metastatic renal cell carcinoma: stage IV
- Second- and subsequent-line advanced or metastatic renal cell carcinoma
- Patient characteristics influencing drug selection in renal cell carcinoma
- Treatment decision tree for renal cell carcinoma: United States
- Treatment decision tree for renal cell carcinoma: EU5
- Treatment decision tree for renal cell carcinoma: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in renal cell carcinoma
- Top unmet needs in renal cell carcinoma: current and future attainment
- Expert insight: unmet need in renal cell carcinoma
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for renal cell carcinoma
- Estimated market authorization dates of key emerging therapies for the treatment of renal cell carcinoma
- Analysis of clinical development program for Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of renal cell carcinoma
- Expert insight: Tecentriq
- Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
- Analysis of the clinical development program for Imfinzi
- Key ongoing clinical trials of Imfinzi in the treatment of renal cell carcinoma
- Expert insight: Imfinzi
- Expectations for market authorization and sales opportunity of Imfinzi in renal cell carcinoma
- Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
- Analysis of clinical development program for tremelimumab and Imfinzi combination therapy
- Key ongoing clinical trials of tremelimumab and Imfinzi combination therapy in the treatment of renal cell carcinoma
- Expert insight: tremelimumab and Imfinzi combination therapy
- Expectations for market authorization and sales opportunity of tremelimumab and Imfinzi combination therapy in renal cell carcinoma
- Analysis of clinical development program for quavonlimab
- Key ongoing clinical trials of quavonlimab in the treatment of renal cell carcinoma
- Expert insight: quavonlimab
- Expectations for market authorization and sales opportunity of quavonlimab in renal cell carcinoma
- Key results from select clinical trials investigating Orpathys for the treatment of renal cell carcinoma
- Analysis of clinical development program for Orpathys
- Key ongoing clinical trials of Orpathys in the treatment of renal cell carcinoma
- Expert insight: Orpathys
- Expectations for market authorization and sales opportunity of Orpathys in renal cell carcinoma
- Key results from select clinical trials investigating abexinostat for the treatment of renal cell carcinoma
- Analysis of clinical development program for abexinostat
- Key ongoing clinical trials of abexinostat in the treatment of renal cell carcinoma
- Expert insight: abexinostat
- Expectations for market authorization and sales opportunity of abexinostat in renal cell carcinoma
- Early-phase pipeline analysis
- Select compounds in early-phase development for renal cell carcinoma
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market considerations in renal cell carcinoma: United States
- General reimbursement environment: United States
- Key market access considerations in renal cell carcinoma: EU5
- General reimbursement environment: EU5
- Key market access considerations in renal cell carcinoma: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Renal cell carcinoma bibliography
- Key findings
Kiran Bountra, M.Res., Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Bountra has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.